» Articles » PMID: 26692418

Role of Senescence Marker P16 INK4a Measured in Peripheral Blood T-lymphocytes in Predicting Length of Hospital Stay After Coronary Artery Bypass Surgery in Older Adults

Overview
Journal Exp Gerontol
Specialty Geriatrics
Date 2015 Dec 23
PMID 26692418
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Adults older than 65 years undergo more than 120,000 coronary artery bypass (CAB) procedures each year in the United States. Chronological age alone, though commonly used in prediction models of outcomes after CAB, does not alone reflect variability in aging process; thus, the risk of complications in older adults. We performed a prospective study to evaluate a relationship between senescence marker p16(INK4a) expression in peripheral blood T-lymphocytes (p16 levels in PBTLs) with aging and with perioperative outcomes in older CAB patients. We included 55 patients age 55 and older, who underwent CAB in Johns Hopkins Hospital between September 1st, 2010 and March 25th, 2013. Demographic, clinical and laboratory data following outline of the Society of Thoracic Surgeons data collection form was collected, and p16 mRNA levels in PBTLs were measured using TaqMan® qRT-PCR. Associations between p16 mRNA levels in PBTLs with length of hospital stay, frailty status, p16 protein levels in the aortic and left internal mammary artery tissue, cerebral oxygen saturation, and augmentation index as a measure of vascular stiffness were measured using regression analyses. Length of hospital stay was the primary outcome of interest, and major organ morbidity, mortality, and discharge to a skilled nursing facility were secondary outcomes. In secondary analysis, we evaluated associations between p16 mRNA levels in PBTLs and interleukin-6 levels using regression analyses. Median age of enrolled patients was 63.5 years (range 56-81 years), they were predominantly male (74.55%), of Caucasian descent (85.45%). Median log2(p16 levels in PBTLs) were 4.71 (range 1.10-6.82). P16 levels in PBTLs were significantly associated with chronological age (mean difference 0.06 for each year increase in age, 95% CI 0.01-0.11) and interleukin 6 levels (mean difference 0.09 for each pg/ml increase in IL-6 levels, 95% CI 0.01-0.18). There were no significant associations with frailty status, augmentation index, cerebral oxygenation and p16 protein levels in blood vessels. Increasing p16 levels in PBTLs did not predict length of stay in the hospital (HR 1.10, 95% CI 0.87-1.40) or intensive care unit (HR 1.02, 95% CI 0.79-1.32). Additional evaluation of p16 levels in PBTLs as predictor of perioperative outcomes is required and should include additional markers of immune system aging as well as different outcomes after CAB in addition to length of hospital stay.

Citing Articles

A Signature of Pre-Operative Biomarkers of Cellular Senescence to Predict Risk of Cardiac and Kidney Adverse Events after Cardiac Surgery.

Entwistle A, Walker S, Knecht A, Strum S, Shah A, Pustavoitau A Cardiol Cardiovasc Med. 2024; 8(3):267-274.

PMID: 39328896 PMC: 11426411. DOI: 10.26502/fccm.92920387.


Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial.

Farr J, Atkinson E, Achenbach S, Volkman T, Tweed A, Vos S Nat Med. 2024; 30(9):2605-2612.

PMID: 38956196 PMC: 11705617. DOI: 10.1038/s41591-024-03096-2.


Cellular Senescence in Immunity against Infections.

Marrella V, Facoetti A, Cassani B Int J Mol Sci. 2022; 23(19).

PMID: 36233146 PMC: 9570409. DOI: 10.3390/ijms231911845.


Immune Senescence, Immunosenescence and Aging.

Lee K, Flores R, Jang I, Saathoff A, Robbins P Front Aging. 2022; 3:900028.

PMID: 35821850 PMC: 9261375. DOI: 10.3389/fragi.2022.900028.


T lymphocyte senescence is attenuated in Parkinson's disease.

Kouli A, Jensen M, Papastavrou V, Scott K, Kolenda C, Parker C J Neuroinflammation. 2021; 18(1):228.

PMID: 34645462 PMC: 8513368. DOI: 10.1186/s12974-021-02287-9.


References
1.
Zindy F, Quelle D, Roussel M, Sherr C . Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene. 1997; 15(2):203-11. DOI: 10.1038/sj.onc.1201178. View

2.
Coppe J, Desprez P, Krtolica A, Campisi J . The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010; 5:99-118. PMC: 4166495. DOI: 10.1146/annurev-pathol-121808-102144. View

3.
Fried L, Tangen C, Walston J, Newman A, Hirsch C, Gottdiener J . Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56(3):M146-56. DOI: 10.1093/gerona/56.3.m146. View

4.
Mitnitski A, Graham J, Mogilner A, Rockwood K . Frailty, fitness and late-life mortality in relation to chronological and biological age. BMC Geriatr. 2002; 2:1. PMC: 88955. DOI: 10.1186/1471-2318-2-1. View

5.
Kim W, Sharpless N . The regulation of INK4/ARF in cancer and aging. Cell. 2006; 127(2):265-75. DOI: 10.1016/j.cell.2006.10.003. View